![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
HD Beall, AM Murphy, D Siegel, RH Hargreaves, J Butler and D Ross
School of Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA.
Bioreductive antitumor quinones require reductive metabolism to produce their cytotoxic effects. A series of these compounds was screened for relative rates of reduction by the two-electron reductase, NAD(P)H:quinone oxidoreductase (DTD). The antitumor quinones streptonigrin (SN), 2,5-diaziridinyl-3-phenyl-1,4-benzoquinone (PDZQ), 2,5-diaziridinyl-3,6-dimethyl-1,4-benzoquinine (MeDZQ), and [3- hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)-propen ol] (EO9) were all excellent substrates for recombinant rat and human DTD. All four compounds were reduced by DTD at least 100 times faster than the clinically important bioreductive alkylating agent, mitomycin C (MC). Reduction of the antitumor quinones was generally 4-5 times more efficient by rat DTD than by human DTD. The exception was EO9, which, surprisingly, was reduced 23 times faster by rat DTD than by human DTD. The rate of reduction of each individual quinone was similar under either aerobic or anaerobic conditions, suggesting that DTD may be an important activating enzyme in the hypoxic fraction of solid tumors. The cytotoxicity of MeDZQ and MC was examined in a panel of human breast and lung cancer cell lines. The data showed good correlations between DTD activity and toxicity for both MeDZQ (r = 0.57, p = 0.054) and MC (r = 0.69, p = 0.020), confirming biochemical data that both compounds are bioactivated by DTD. In addition, IC50 values were in general lower for MeDZQ than for MC in cell lines containing elevated DTD, a finding that was consistent with metabolic data that indicated that MeDZQ was a better substrate for DTD than MC. SR, defined as the ratio of the IC50 value for the H596 NSCLC cell line (undetectable DTD activity) to the IC50 value for the H460 NSCLC cell line (high DTD activity), were determined for all five antitumor quinones. SN was the most selective (SR = 86) followed by EO9 (SR = 62), MeDZQ (SR = 17), and MC (SR = 11). Surprisingly, PDZQ, an excellent substrate for DTD, was toxic to both cell lines (SR = 1.8). These data suggest that antitumor quionones that are substrates for DTD may be selectively toxic to tumors with high DTD activity and may be useful in the treatment of those tumors.
This article has been cited by other articles:
|
|
 |
|
  T. H. Ward, S. Danson, A. T. McGown, M. Ranson, N. A. Coe, G. C. Jayson, J. Cummings, R. H.J. Hargreaves, and J. Butler Preclinical Evaluation of the Pharmacodynamic Properties of 2,5-Diaziridinyl-3-Hydroxymethyl-6-Methyl-1,4-Benzoquinone Clin. Cancer Res., April 1, 2005; 11(7): 2695 - 2701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Dehn, S. L. Winski, and D. Ross Development of a New Isogenic Cell-Xenograft System for Evaluation of NAD(P)H:Quinone Oxidoreductase-Directed Antitumor Quinones: Evaluation of the Activity of RH1 Clin. Cancer Res., May 1, 2004; 10(9): 3147 - 3155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Zappa, T. Ward, E. Pedrinis, J. Butler, and A. McGown NAD(P)H:Quinone Oxidoreductase 1 Expression in Kidney Podocytes J. Histochem. Cytochem., March 1, 2003; 51(3): 297 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Zappa, T. Ward, J. Butler, E. Pedrinis, and A. McGown Overexpression of NAD(P)H:quinone oxidoreductase 1 in Human Reproductive System J. Histochem. Cytochem., September 1, 2001; 49(9): 1187 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Sharp, L. R. Kelland, M. R. Valenti, L. A. Brunton, S. Hobbs, and P. Workman Establishment of an Isogenic Human Colon Tumor Model for NQO1 Gene Expression: Application to Investigate the Role of DT-Diaphorase in Bioreductive Drug Activation In Vitro and In Vivo Mol. Pharmacol., November 1, 2000; 58(5): 1146 - 1155. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. J. Knox, T. C. Jenkins, S. M. Hobbs, S. Chen, R. G. Melton, and P. J. Burke Bioactivation of 5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by Human NAD(P)H Quinone Oxidoreductase 2: A Novel Co-substrate-mediated Antitumor Prodrug Therapy Cancer Res., August 1, 2000; 60(15): 4179 - 4186. [Abstract] [Full Text]
|
|
|
|
|
|
L. M. Siemankowski, J. Morreale, B. D. Butts, and M. M. Briehl Increased Tumor Necrosis Factor-{{alpha}} Sensitivity of MCF-7 Cells Transfected with NAD(P)H:Quinone Reductase Cancer Res., July 1, 2000; 60(13): 3638 - 3644. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. J. Pink, S. M. Planchon, C. Tagliarino, M. E. Varnes, D. Siegel, and D. A. Boothman NAD(P)H:Quinone Oxidoreductase Activity Is the Principal Determinant of beta -Lapachone Cytotoxicity J. Biol. Chem., February 25, 2000; 275(8): 5416 - 5424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Belcourt, W. F. Hodnick, S. Rockwell, and A. C. Sartorelli The Intracellular Location of NADH:Cytochrome b5 Reductase Modulates the Cytotoxicity of the Mitomycins to Chinese Hamster Ovary Cells J. Biol. Chem., April 10, 1998; 273(15): 8875 - 8881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Zhao, X. L. Yang, W. D. Holtzclaw, and P. Talalay Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase) PNAS, March 4, 1997; 94(5): 1669 - 1674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Moussa, P. Houziaux, B. Danree, and R. Azerad Microbial Models of Mammalian Metabolism. Fungal Metabolism of Phenolic and Nonphenolic p-Cymene-Related Drugs and Prodrugs. I. Metabolites of Thymoxamine Drug Metab. Dispos., March 1, 1997; 25(3): 301 - 310. [Abstract] [Full Text]
|
|
|
|
|
|
M. Faig, M. A. Bianchet, P. Talalay, S. Chen, S. Winski, D. Ross, and L. M. Amzel Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: Species comparison and structural changes with substrate binding and release PNAS, March 28, 2000; 97(7): 3177 - 3182. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
